{"denoms":[{"counts":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"39"},{"groupId":"BG006","value":"110"}],"units":"Participants"}],"groups":[{"description":"Patients receive lenalidomide 15 mg PO on days 1-21 and25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"BG000","title":"Phase I, All Histologies, Lenalidomide 15 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"BG001","title":"Phase I, All Histologies, Lenalidomide 20 mg"},{"description":"Patients receive lenalidomide 25 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"BG002","title":"Phase I, All Histologies, Lenalidomide 25 mg"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"BG003","title":"Phase II, Diffuse Large B-Cell Subtype"},{"description":"Patients receive lenalidomide 20mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"BG004","title":"Phase II, Follicular Subtype"},{"description":"Patients receive lenalidomide 20 mg PO on days 1-21 and 25 mg temsirolimus IV over 30 minutes on days 1, 8, 15, and 22. Treatment repeats every 28 days for 2 courses in the absence of disease progression or unacceptable toxicity. .","id":"BG005","title":"Phase II, Lymphoma NOS"},{"description":"Total of all reporting groups","id":"BG006","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","lowerLimit":"41","upperLimit":"73","value":"60.9"},{"groupId":"BG001","lowerLimit":"56","upperLimit":"77","value":"65.2"},{"groupId":"BG002","lowerLimit":"41","upperLimit":"80","value":"65.3"},{"groupId":"BG003","lowerLimit":"25","upperLimit":"78","value":"64.1"},{"groupId":"BG004","lowerLimit":"43","upperLimit":"76","value":"63.3"},{"groupId":"BG005","lowerLimit":"23","upperLimit":"72","value":"47.4"},{"groupId":"BG006","lowerLimit":"23","upperLimit":"80","value":"57.9"}]}]}],"dispersionType":"FULL_RANGE","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"11"},{"groupId":"BG004","value":"6"},{"groupId":"BG005","value":"14"},{"groupId":"BG006","value":"36"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"7"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"3"},{"groupId":"BG003","value":"28"},{"groupId":"BG004","value":"9"},{"groupId":"BG005","value":"25"},{"groupId":"BG006","value":"74"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"1"}],"title":"American Indian or Alaska Native"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"1"},{"groupId":"BG005","value":"1"},{"groupId":"BG006","value":"3"}],"title":"Asian"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"Native Hawaiian or Other Pacific Islander"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"4"},{"groupId":"BG004","value":"2"},{"groupId":"BG005","value":"6"},{"groupId":"BG006","value":"14"}],"title":"Black or African American"},{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"5"},{"groupId":"BG003","value":"33"},{"groupId":"BG004","value":"12"},{"groupId":"BG005","value":"29"},{"groupId":"BG006","value":"88"}],"title":"White"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"},{"groupId":"BG003","value":"0"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"0"},{"groupId":"BG006","value":"0"}],"title":"More than one race"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"1"},{"groupId":"BG003","value":"1"},{"groupId":"BG004","value":"0"},{"groupId":"BG005","value":"2"},{"groupId":"BG006","value":"4"}],"title":"Unknown or Not Reported"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race (NIH/OMB)","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"3"},{"groupId":"BG002","value":"6"},{"groupId":"BG003","value":"39"},{"groupId":"BG004","value":"15"},{"groupId":"BG005","value":"39"},{"groupId":"BG006","value":"110"}]}],"title":"United States"}],"paramType":"NUMBER","title":"Region of Enrollment","unitOfMeasure":"participants"}]}